Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Mar. 09, 2017	Feb. 28, 2015	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2022	Nov. 08, 2022
Fortress [Member]
Percentage of Fully-diluted Outstanding Equity		2.50%
Percentage of Equity or Debt Fnancing		2.50%
Annual Equity Fee Expense			$ 0	$ 0
Financing Equity Fee			100	100
Fortress [Member] \| Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000
Fortress [Member] \| Management Services Agreement [Member]
Costs and Expenses			$ 100	$ 100
Fortress [Member] \| The 2024 Annual Equity Fee [Member]
Stock Issued During Period, Shares, New Issues (in shares)			102,185
Fortress [Member] \| The 2023 Annual Equity Fee [Member]
Stock Issued During Period, Shares, New Issues (in shares)				22,476
Fortress [Member] \| Financing Equity Fee [Member]
Stock Issuable, Shares, New Issuance (in shares)			23,474	5,543
Fortress [Member] \| Research and Development Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
Fortress [Member] \| General and Administrative Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
BaergicBio, Inc.[Member] \| Avenue Baergic Founders Agreement [Member]
Percentage of Equity Fee						2.50%
Percentage Of Additional Consideration Of Equity Fee					2.50%
Percentage Considered For The Calculation Of One-Time Fee					4.50%
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500
Increase in Annual Consulting Fee	$ 1,000

AVENUE THERAPEUTICS, INC. 10-Q